| Literature DB >> 28611667 |
Xiaorui Wu1,2, Dong Li3, Junlian Liu2, Lihong Diao3, Shukuan Ling2, Yuheng Li2, Jianyi Gao2, Quanchun Fan2, Weijia Sun2, Qi Li2, Dingsheng Zhao2, Guohui Zhong2, Dengchao Cao2, Min Liu4, Jiaping Wang2, Shuang Zhao2, Yu Liu2, Guie Bai2, Hongzhi Shi2, Zi Xu2, Jing Wang2, Chunmei Xue2, Xiaoyan Jin2, Xinxin Yuan2, Hongxing Li2, Caizhi Liu2, Huiyuan Sun5, Jianwei Li2, Yongzhi Li1,2, Yingxian Li2.
Abstract
Increasing evidence indicates the occurrence of cognitive impairment in astronauts under spaceflight compound conditions, but the underlying mechanisms and countermeasures need to be explored. In this study, we found that learning and memory abilities were significantly reduced in rats under a simulated long-duration spaceflight environment (SLSE), which includes microgravity, isolation confinement, noises, and altered circadian rhythms. Dammarane sapogenins (DS), alkaline hydrolyzed products of ginsenosides, can enhance cognition function by regulating brain neurotransmitter levels and inhibiting SLSE-induced neuronal injury. Bioinformatics combined with experimental verification identified that the PI3K-Akt-mTOR pathway was inhibited and the MAPK pathway was activated during SLSE-induced cognition dysfunction, whereas DS substantially ameliorated the changes in brain. These findings defined the characteristics of SLSE-induced cognitive decline and the mechanisms by which DS improves it. The results provide an effective candidate for improving cognitive function in spaceflight missions.Entities:
Keywords: BDNF; MAPK; PI3K/AKT; cognitive; dammarane sapogenins; neurotransmitter; rat models; space flight
Year: 2017 PMID: 28611667 PMCID: PMC5446991 DOI: 10.3389/fphar.2017.00315
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Parameters of neurotransmitter for MS condition.
| Analyte | Declustering potential (V) | Entrance potential (V) | Collision energy (eV) | Collision cell exit potential (V) | ||
|---|---|---|---|---|---|---|
| 5-HT | 177 | 160 | 65 | 12 | 10 | 8 |
| DA | 154.2 | 136.6 | 30 | 12 | 15 | 40 |
| NE | 170 | 152 | 95 | 12 | 15 | 10 |
| E | 184 | 165.8 | 40 | 7 | 12 | 15 |
| Glu | 148 | 84 | 95 | 4 | 17 | 9 |
| GABA | 104.1 | 87 | 50 | 10 | 17 | 8 |
| ACh | 146.1 | 87.4 | 160 | 10 | 20 | 30 |